Interim Analysis of a Phase 2 Open‐Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor‐Induced Osteomalacia

Patients with tumor‐induced osteomalacia (TIO), an acquired paraneoplastic condition characterized by osteomalacia due to hypophosphatemia, exhibit a similar clinical picture to those with X‐linked hypophosphatemic rickets/osteomalacia (XLH). The human monoclonal anti‐fibroblast growth factor 23 (FG...

Descripción completa

Detalles Bibliográficos
Autores principales: Imanishi, Yasuo, Ito, Nobuaki, Rhee, Yumie, Takeuchi, Yasuhiro, Shin, Chan Soo, Takahashi, Yutaka, Onuma, Hiroki, Kojima, Masahiro, Kanematsu, Masanori, Kanda, Hironori, Seino, Yoshiki, Fukumoto, Seiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988547/
https://www.ncbi.nlm.nih.gov/pubmed/32967046
http://dx.doi.org/10.1002/jbmr.4184

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988547/
https://www.ncbi.nlm.nih.gov/pubmed/32967046
http://dx.doi.org/10.1002/jbmr.4184

Ejemplares similares